Fine specificity of autoantibodies to calreticulin: Epitope mapping and characterization

Clinical and Experimental Immunology

Volumn 120, Issue 2, 2000, Pages 384-391

  Eggleton, P ^a   Ward, F J ^b   Johnson, S ^a   Khamashta, M A ^c   Hughes, G R V ^c   Hajela, V A ^c   Michalak, M ^d   Corbett, E F ^d   Staines, N A ^b   Reid, K B M ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c ST THOMAS HOSPITAL   (United Kingdom)

^d UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Autoimmune disease; Calreticulin epitope; Systemic lupus erythematosus

Indexed keywords

CALRETICULIN; COMPLEMENT COMPONENT C1Q;

ADULT; ANTIBODY SPECIFICITY; ARTICLE; AUTOIMMUNE DISEASE; CLINICAL ARTICLE; COMPLEMENT INHIBITION; CONTROLLED STUDY; ENDOPLASMIC RETICULUM; EPITOPE MAPPING; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PREDICTION; PRIORITY JOURNAL;

ADULT; AMINO ACID SEQUENCE; ANTIBODY SPECIFICITY; AUTOANTIBODIES; AUTOANTIGENS; CALCIUM-BINDING PROTEINS; CALRETICULIN; EPITOPE MAPPING; EPITOPES, B-LYMPHOCYTE; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MOLECULAR SEQUENCE DATA; RIBONUCLEOPROTEINS; SJOGREN'S SYNDROME;

EID: 0034024804     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2000.01214.x     Document Type: Article

References (34)

1. 1 Boehm J, Orth T, Van Nguyen P et al. Systemic lupus erythematosus is associated with increased auto-antibody titres against calreticulin and grp94, but calreticulin is not the Ro/SS-A antigen. Eur J Clin Invest 1994; 24:248-57.
2. 2 Kishore U, Sontheimer RD, Sastry KN et al. The systemic lupus erythematosus (SLE) disease autoantigen-calreticulin can inhibit C1q association with immune complexes. Clin Exp Immunol 1997; 108:181-90.
3. 3 Ben-Chetrit E. The molecular basis of the SSA/Ro antigens and the clinical significance of their autoantibodies. Br J Rheumatol 1993; 32:396-402.
4. 4 Eggleton P, Reid KB, Kishore U et al. Clinical relevance of calreticulin in systemic lupus erythematosus. Lupus 1997; 6:564-71.
5. 5 Karska K, Tuckova L, Steiner L et al. Calreticulin - the potential autoantigen in celiac disease. Biochem Biophys Res Commun 1995; 209:597-605.
6. 6 Orth T, Dorner T, Meyer Zum Buschenfelde KH et al. Complete congenital heart block is associated with increased autoantibody titres against calreticulin. Eur J Clin Invest 1996; 26:205-15.
7. 7 Bonnefoy S, Attal G, Langsley G et al. Molecular characterization of the heat shock protein 90 gene of the human malaria parasite Plasmodium falciparum. Mol Biochem Parasitol 1994; 67:157-70.
8. 8 Rokeach LA, Zimmerman PA, Unnasch TR. Epitopes of the Onchocerca volvulus RAL1 antigen, a member of the calreticulin family of proteins, recognized by sera from patients with onchocerciasis. Infect Immun 1994; 62:3696-704.
9. 9 Khalife J, Trottein F, Schacht AM et al. Cloning of the gene encoding a Schistosoma mansoni antigen homologous to human Ro/SS-A autoantigen. Mol Biochem Parasitol 1993; 57:193-202.
10. 10 Sanders ML, Jaworski DC, Sanchez JL et al. Antibody to a cDNA-derived calreticulin protein from Amblyomma americanum as a biomarker of tick exposure in humans. Am J Trop Med Hyg 1998; 59:279-85.
11. 11 Eggleton P, Llewellyn D. Pathophysiological roles of calreticulin in autoimmune disease. Scand J Immunol 1999; 49:466-73.
12. 12 Cheng ST, Nguyen TQ, Yang YS et al. Calreticulin binds hYRNA and the 52-kDa polypeptide component of the Ro/SS-A ribonucieoprotein autoantigen. J Immunol 1996; 156:4484-91.
13. 13 Kinoshita G, Keech CL, Sontheimer RD et al. Spreading of the immune response from 52 kDaRo and 60 kDaRo to calreticulin in experimental autoimmunity. Lupus 1998; 7:7-11.
14. 14 Lieu TS, Newkirk MM, Capra JD et al. Molecular characterization of human Ro/SS-A antigen. Amino terminal sequence of the protein moiety of human Ro/SS-A antigen and immunological activity of a corresponding synthetic peptide. J Clin Invest 1988; 82:96-101.
15. 15 Lieu TS, Newkirk MM, Arnett FC et al. A major autoepitope is present on the amino terminus of a human SS-A/Ro polypeptide. J Autoimmun 1989; 2:367-74.
16. 16 Rosen A, Casciola-Rosen L. Autoantigens as substrates for apoptotic proteases: implications for the pathogenesis of systemic autoimmune disease. Cell Death Differ 1999; 6:6-12.
17. 17 Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25:1271-7.
18. 18 Petri M, Genovese M, Engle E et al. Clinical definition, incidence, and clinical description of flare in systemic lupus erythematosus. Arthritis Rheum 1991; 34:937-44.
19. 19 Vitali C, Bombardieri S, Moutsopoulos HM et al. Preliminary criteria for the classification of Sjogren's syndrome. Results of a prospective concerted action supported by the European Community. Arthritis Rheum 1993; 36:340-7.
20. 20 Harris EN. Antiphospholipid antibodies. Br J Haematol 1990; 74:1-9.
21. 21 Baksh S, Burns K, Andrin C et al. Interaction of calreticulin with protein disulphide isomerase. J Biol Chem 1995; 270:31338-44.
22. 22 Kishore U, Sontheimer RD, Sastry KN et al. Release of calreticulin from neutrophils may alter C1q-mediated immune functions. Biochem J 1997; 322:543-50.
23. 23 Kovacs H, Campbell ID, Strong P et al. Evidence that C1q binds specifically to CH2-like immunoglobulin gamma motifs present in the autoantigen calreticulin and interferes with complement activation. Biochemistry 1998; 37:17865-74.
24. 24 Parker JM, Guo D, Hodges RS. New hydrophilicity scale derived from high-performance liquid chromatography peptide retention data: correlation of predicted surface residues with antigenicity and X-ray-derived accessible sites. Biochemistry 1986; 25:5425-32.
25. 25 Sontheimer RD, Lieu TS, McCauliffe DP. Molecular characterization of the Ro/SS-A autoimmune response. Semin Dermatol 1991; 10:199-205.
26. 26 Routsias JG, Tzioufas AG, Sakarellos-Daitsiotis M et al. Calreticulin synthetic peptide analogues: anti-peptide antibodies in autoimmune rheumatic diseases. Clin Exp Immunol 1993; 91:437-41.
27. 27 Meldolesi J, Krause K-H, Michalak M. Calreticulin: how many functions in how many cellular compartments? Cell Calcium 1996; 20:83-86.
28. 28 Casciola Rosen L, Rosen A, Petri M et al. Surface blebs on apoptotic cells are sites of enhanced procoagulant activity: implications for coagulation events and antigenic spread in systemic lupus erythematosus. Proc Natl Acad Sci USA 1996; 93:1624-9.
29. 29 Pike SE, Yao L, Jones KD et al. Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumour growth. J Exp Med 1999; 188:2349-56.
30. 30 Deshmukh US, Lewis JE, Gaskin F et al. Immune responses to Ro60 and its peptides in mice. I. The nature of the immunogen and endogenous autoantigen determine the specificities of the induced autoantibodies. J Exp Med 1999; 189:531-40.
31. 31 Caponi L, Bombardieri S, Migliorini P. Anti-ribosomal antibodies bind the Sm proteins D and B/B'. Clin Exp Immunol 1998; 112:139-43.
32. 32 Krupicková S, Tucková L, Flegelová Z et al. Identification of common epitopes on gliadin, enterocytes, and calreticulin recognized by antigliadin antibodies of patients with coeliac disease. Gut 1999; 44:168-73.
33. 33 Sontheimer RD, Nguyen TQ. Cheng ST et al. The unveiling of calreticulin - a clinically relevant tour of modern cell biology. J Invest Med 1995; 43:362-70.
34. 34 Lieu TS, Reimer CB, Sontheimer RD. Immunoglobulin class and subclass profile of the Ro/SS-A autoantibody response. J Invest Dermatol 1988; 90:158-64.